Sublingual buprenorphine is a safe and effective alternative to methadone for treating opioid dependence during pregnancy, finds the Maternal Opioid Treatment: Human Experimental Research (MOTHER) study, a NIDA-supported clinical trial. Women who received either medication had similar pregnancy and birth outcomes, but infants born to women who received buprenorphine had milder symptoms of neonatal opioid withdrawal.

Methadone treatment centers are not foci for serious criminal activity, according to a study that used crime reports and global positioning data to compare crime rates at various distances around methadone centers, hospitals, convenience stores, and residential neighborhoods.

Reports findings from a survey that revealed that although substance abuse is prevalent in jails and prisons, many correctional facilities do not offer detoxification services or therapies to aid in maintaining abstinence.

Dr. Marilyn Huestis of NIDA’s Intramural Research Program talks about conducting research on drug effects with human subjects, developing tests to help law enforcement identify drugged drivers, and an assay to help identify children whose prenatal exposure to anti-HIV drugs may put them at risk for adverse developmental outcomes.

Two recent studies suggest that genotyping may enable clinicians to base therapies on individual patients’ potential responsiveness to opioid drugs’ therapeutic effects and vulnerability to their harmful effects.